How I treat thalassemia

Blood

Volumn 118, Issue 13, 2011, Pages 3479-3488

  Rachmilewitz, Eliezer A ^a   Giardina, Patricia J ^b  

^a WOLFSON MEDICAL CENTER   (Israel)

^b NEW YORK PRESBYTERIAN HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEFERASIROX; DEFERIPRONE; DEFEROXAMINE; DEFEROXAMINE MESYLATE; ENDONUCLEASE; HEMOGLOBIN; IRON; TRANSFERRIN;

AFRICA; ALPHA THALASSEMIA; ANEMIA; ASIA; BETA THALASSEMIA; BLOOD GROUP TYPING; BONE DISEASE; CAUSE OF DEATH; CELL INCLUSION; CORD BLOOD STEM CELL TRANSPLANTATION; DYSERYTHROPOIESIS; ERYTHROCYTE LIFESPAN; ERYTHROCYTE TRANSFUSION; FAMILY HISTORY; GENE DELETION; GENETIC COUNSELING; GENOTYPE; HEART ARRHYTHMIA; HEART FAILURE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMOGLOBIN SYNTHESIS; HEMOLYSIS; HEPATOSPLENOMEGALY; HUMAN; HYPERCOAGULABILITY; HYPOXIA; INCIDENCE; IRON ABSORPTION; IRON CHELATION; IRON DEFICIENCY; IRON DEFICIENCY ANEMIA; IRON OVERLOAD; LOSS OF FUNCTION MUTATION; LYMPHADENOPATHY; MIDDLE EAST; NORTH AFRICA; NUCLEIC ACID HYBRIDIZATION; PATHOPHYSIOLOGY; PERICARDITIS; PRENATAL CARE; PRENATAL DIAGNOSIS; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SOUTHEAST ASIA; SOUTHERN EUROPE; SPLENECTOMY; STOP CODON; THALASSEMIA;

EID: 80053364446     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-08-300335     Document Type: Review

References (104)

1. Giardina P, Forget B. Thalassemia syndromes. In: Hoffman R, Benz E, Shattil S, et al, eds. Hematology: Basic Principles and Practice (5th ed). Philadelphia, PA: Churchill Livingstone; 2008:535-563.
2. Weatherall DJ. Genetic variation and susceptibility to infection: the red cell and malaria. Br J Haematol. 2008;141(3):276-286. (Pubitemid 351521151)
3. Weatherall DJ. The inherited diseases of hemoglobin are an emerging global health burden. Blood. 2010;115(22):4331-4336.
4. Weatherall D. The thalassemias. In: Stamatoyannopoulos G, Nienhuis A, Majerus P, eds. Molecular Basis of Blood Diseases (2nd ed). Philadelphia, PA: Saunders; 1994:157.
5. Rund D, Rachmilewitz E. Beta-thalassemia. N Engl J Med. 2005;353(11):1135-1146.
6. Schwartz E Jr. Thalassemia syndromes. In: Miller D, Baehner R, eds. Smith's Blood Diseases of Infancy and Childhood (6th ed). St Louis, MO: Mosby; 1989:428.
7. Fibach E, Rachmilewitz E. The role of oxidative stress in hemolytic anemia. Curr Mol Med. 2008; 8(7):609-619.
8. Kalpravidh RW, Siritanaratkul N, Insain P, et al. Improvement in oxidative stress and antioxidant parameters in beta-thalassemia/Hb E patients treated with curcuminoids. Clin Biochem. 2010; 43(4):424-429.
9. Fibach E, Tan ES, Jamuar S, Ng I, Amer J, Rachmilewitz EA. Amelioration of oxidative stress in red blood cells from patients with beta-thalassemia major and intermedia and E-beta-thalassemia following administration of a fermented papaya preparation. Phytother Res. 2010;24(9): 1334-1338.
10. Fucharoen S, Viprakasit V. HbH disease: clinical course and disease modifiers. Am Soc Hematol Educ Program. 2009:26-34.
11. Singer ST, Kim HY, Olivieri NF, et al. Hemoglobin H-constant spring in North America: an alpha thalassemia with frequent complications. Am J Hematol. 2009;84(11):759-761.
12. Schuman J, Tanser CL, Peloquin R, De Leeuw NK. The erythropoietic response to pregnancy in beta-thalassemia minor. Br J Haematol. 1973;25(2):249- 260.
13. Taher AT, Mussallam KM, Karimi M, et al. Overview on practices in thalassemia intermedia management aiming for lowering complication rates across a region of endemicity: the OPTIMAL CARE study. Blood. 2010;115(10):1886-1892.
14. Borgna-Pignatti C. Modern treatment of thalassaemia intermedia. Br J Haematol. 2007;138(3): 291-304. (Pubitemid 47035387)
15. Aessopos A, Farmakis D, Karagiorga M, et al. Cardiac involvement in thalassemia intermedia: a multicenter study. Blood. 2001;97(11):3411-3416.
16. Aessopos A, Farmakis D, Deftereos S, et al. Thalassemia heart disease: a comparative evaluation of thalassemia major and thalassemia intermedia. Chest. 2005;127(5):1523-1530. (Pubitemid 46218775)
17. Atichartakarn V, Chuncharunee S, Chandanamattha P, et al. Correction of hypercoagulability and amelioration of pulmonary arterial hypertension by chronic blood transfusion in an asplenic hemoglobin E/beta-thalassemia patient. Blood. 2004;103(7):2844-2846. (Pubitemid 38393049)
18. Aessopos A, Kati M, Meletis J. Thalassemia intermedia today: should patients regularly receive transfusions? Transfusion. 2007;47(5):792-800. (Pubitemid 46668992)
19. Wood JC, Enriquez C, Ghugre N, et al. MRI R2 and R2*mapping accurately estimates hepatic iron concentration in transfusion-dependent thalassemia and sickle cell disease patients. Blood. 2005;106(4):1460-1465. (Pubitemid 41129616)
20. Taher A, Hershko C, Cappellini MD. Iron overload in thalassaemia intermedia: reassessment of iron chelation strategies. Br J Haematol. 2009;147(5): 634-640.
21. Cooley T, Lee P. A series of cases of splenomegaly in children with anemia and peculiar bone changes. Trans Am Pediatr. 1925;37:29-30.
22. Di Marco V, Capra M, Angelucci E, et al. Management of chronic viral hepatitis in patients with thalassemia: recommendations from an international panel. Blood. 2010;116(16):2875-2883.
23. Grabowski EF, Giardina PJ, Goldberg D, et al. Babesiosis transmitted by a transfusion of frozen-thawed blood. Ann Intern Med. 1982;96(4):466-467. (Pubitemid 12139876)
24. Piomelli S, Graziano J, Karpatkin M, et al. Chelation therapy, transfusion requirement, and iron balance in young thalassemic patients. Ann N Y Acad Sci. 1980;344:409-417. (Pubitemid 11140750)
25. Piomelli S, Hart D, Graziano J, et al. Current strategies in the management of Cooley's anemia. Ann N Y Acad Sci. 1985;445:256-267. (Pubitemid 15247922)
26. Cohen AR, Glimm E, Porter JB. Effect of transfusional iron intake on response to chelation therapy in beta-thalassemia major. Blood. 2008; 111(2):583-587.
27. Modell B, Khan M, Darlison M. Survival in beta-thalassaemia major in the UK: data from the UK Thalassaemia Register. Lancet. 2000;355(9220): 2051-2052. (Pubitemid 30339248)
28. Ehlers KH, Giardina PJ, Lesser ML, Engle MA, Hilgartner MW. Prolonged survival in patients with beta-thalassemia major treated with deferoxamine. J Pediatr. 1991;118(4):540-545.
29. Kirk P, Roughton M, Porter JB, et al. Cardiac T2*magnetic resonance for prediction of cardiac complications in thalassemia major. Circulation. 2009;120(20):1961-1968.
30. Pakakasama S, Wanitkun S, Hongeng S. Pericarditis occurring with engraftment syndrome in a thalassemic patient. Bone Marrow Transplant. 2004;34(9):819-820. (Pubitemid 39467895)
31. Engle MA, Erlandson M, Smith CH. Late cardiac complications of chronic, severe, refractory anemia with hemochromatosis. Circulation. 1964;30: 698-705.
32. Angelucci E, Mariotti E, Lucarelli G, et al. Sudden cardiac tamponade after chemotherapy for marrow transplantation in thalassaemia. Lancet. 1992;339(8788):287-289.
33. Piomelli S, Karpatkin MH, Arzanian M, et al. Hypertransfusion regimen in patients with Cooley's anemia. Ann N Y Acad Sci. 1974;232(0):186-192.
34. De Sanctis V, Eleftheriou A, Malaventura C. Prevalence of endocrine complications and short stature in patients with thalassaemia major: a multicenter study by the Thalassaemia International Federation (TIF). Pediatr Endocrinol Rev. 2004;2(suppl 2):249-255.
35. Vogiatzi MG, Macklin EA, Trachtenberg FL, et al. Differences in the prevalence of growth, endocrine and vitamin D abnormalities among the various thalassaemia syndromes in North America. Br J Haematol. 2009;146(5):546-556.
36. Vogiatzi MG, Macklin EA, Fung EB, et al. Bone disease in thalassemia: a frequent and still unresolved problem. J Bone Miner Res. 2009;24(3): 543-557.
37. Cunningham MJ, Macklin EA, Neufeld EJ, Cohen AR. Complications of beta-thalassemia major in North America. Blood. 2004;104(1):34-39. (Pubitemid 38879833)
38. Cappellini MD, Robbiolo L, Bottasso BM, Coppola R, Fiorelli G, Mannucci AP. Venous thromboembolism and hypercoagulability in splenectomized patients with thalassaemia intermedia. Br J Haematol. 2000;111(2):467-473. (Pubitemid 32009338)
39. Ataga KI, Cappellini MD, Rachmilewitz EA. Beta-thalassaemia and sickle cell anaemia as paradigms of hypercoagulability. Br J Haematol. 2007; 139(1):3-13. (Pubitemid 47389919)
40. Eldor A, Rachmilewitz EA. The hypercoagulable state in thalassemia. Blood. 2002;99(1):36-43.
41. Ruf A, Pick M, Deutsch V, et al. In-vivo platelet activation correlates with red cell anionic phospholipid exposure in patients with beta-thalassaemia major. Br J Haematol. 1997;98(1):51-56. (Pubitemid 27348794)
42. Taher A, Isma'eel H, Mehio G, et al. Prevalence of thromboembolic events among 8860 patients with thalassaemia major and intermedia in the Mediterranean area and Iran. Thromb Haemost. 2006;96(4):488-491. (Pubitemid 44560684)
43. Karimi M, Bagheri H, Rastgu F, Rachmilewitz EA. Magnetic resonance imaging to determine the incidence of brain ischaemia in patients with beta-thalassaemia intermedia. Thromb Haemost. 2010;103(5):989-993.
44. Engelhard D, Cividalli G, Rachmilewitz EA. Splenectomy in homozygous beta thalassaemia: a retrospective study of 30 patients. Br J Haematol. 1975;31(3):391-403.
45. Cohen A, Gayer R, Mizanin J. Long-term effect of splenectomy on transfusion requirements in thalassemia major. Am J Hematol. 1989;30(4): 254-256. (Pubitemid 19087317)
46. Graziano JH, Piomelli S, Hilgartner M, et al. Chelation therapy in beta-thalassemia major: III. The role of splenectomy in achieving iron balance. J Pediatr. 1981;99(5):695-699. (Pubitemid 12229134)
47. Odame I, Rund D. Evidence-based treatment of thalassemia major. In: Crowther M, Ginsberg J, Schunemann H, Meyer R, Lottenberg R, eds. Evidence-Based Hematology. Boston, MA: Blackwell; 2008:251-259.
48. Ikeda M, Sekimoto M, Takiguchi S, et al. High incidence of thrombosis of the portal venous system after laparoscopic splenectomy: a prospective study with contrast-enhanced CT scan. Ann Surg. 2005;241(2):208-216.
49. Pippard M. Iron chelation therapy in the treatment of iron overload. In: Bergeron R, Brittenham G, eds. The Development of Iron Chelators for Clinical Use. Boca Raton, FL: CRC Press; 1994:57-74.
50. Tanno T, Bhanu NV, Oneal PA, et al. High levels of GDF15 in thalassemia suppress expression of the iron regulatory protein hepcidin. Nat Med. 2007;13(9):1096-1101. (Pubitemid 47517510)
51. Gardenghi S, Marongiu MF, Ramos P, et al. Ineffective erythropoiesis in beta thalassemia is characterized by increased iron absorption mediated by down regulation of hepcidin and up regulation of ferroportin. Blood. 2007;109(11):5027-5035. (Pubitemid 46827803)
52. Origa R, Galanello R, Ganz T, et al. Liver iron concentrations and urinary hepcidin in beta-thalassemia. Haematologica. 2007;92(5):583-588. (Pubitemid 350144260)
53. Giardina PJ, Grady RW. Chelation therapy in beta-thalassemia: an optimistic update. Semin Hematol. 2001;38(4):360-366. (Pubitemid 32995605)
54. Neufeld EJ. Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: new data, new questions. Blood. 2006;107(9):3436-3441.
55. Borgna-Pignatti C, Rugolotto S, De Stefano P, et al. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica. 2004;89(10): 1187-1193. (Pubitemid 39390442)
56. Olivieri NF. The beta-thalassemias. N Engl J Med. 1999;341(2):99-109.
57. Cabantchik ZI, Breuer W, Zanninelli G, et al. LPI-labile plasma iron in iron overload. Best Pract Res Clin Haematol. 2005;18(2):277-287. (Pubitemid 40298370)
58. Kontoghiorghes GJ, Aldouri MA, Hoffbrand AV, et al. Effective chelation of iron in beta thalassaemia with the oral chelator 1,2-dimethyl-3-hydroxypyrid- 4-one. Br Med J (Clin Res Ed). 1987; 295(6612):1509-1512.
59. Hider RC, Singh S, Porter JB, Huehns ER. The development of hydroxypyridin-4-ones as orally active iron chelators. Ann N Y Acad Sci. 1990; 612:327-338.
60. Olivieri NF, Brittenham GM, Matsui D, et al. Iron-chelation therapy with oral deferiprone in patients with thalassemia major. N Engl J Med. 1995; 332(14):918-922.
61. Hoffbrand AV, AL-Refaie F, Davis B, et al. Long-term trial of deferiprone in 51 transfusion-dependent iron overloaded patients. Blood. 1998;91(1): 295-300.
62. Maggio A, D'Amico G, Morabito A, et al. Deferiprone versus deferoxamine in patients with thalassemia major: a randomized clinical trial. Blood Cells Mol Dis. 2002;28(2):196-208. (Pubitemid 34743754)
63. Piga A, Gaglioti C, Fogliacco E, Tricta F. Comparative effects of deferiprone and deferoxamine on survival and cardiac disease in patients with thalassemia major: a retrospective analysis. Haematologica. 2003;88(5):489-496. (Pubitemid 36648438)
64. Cohen AR, Galanello R, Piga A, De Sanctis V, Tricta F. Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone. Blood. 2003;102(5):1583-1587. (Pubitemid 37022545)
65. Cohen AR, Galanello R, Piga A, Dipalma A, Vullo C, Tricta F. Safety profile of the oral iron chelator deferiprone: a multicentre study. Br J Haematol. 2000;108(2):305-312. (Pubitemid 30143646)
66. Nisbet-Brown E, Olivieri NF, Giardina PJ, et al. Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet. 2003;361(9369):1597-1602. (Pubitemid 36578996)
67. Cappellini MD, Cohen A, Piga A, et al. A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. Blood. 2006;107(9):3455-3462.
68. Pennell DJ, Porter JB, Cappellini MD, et al. Efficacy of deferasirox in reducing and preventing cardiac iron overload in beta-thalassemia. Blood 2010;115(12):2364-2371.
69. Hershko C, Konijn AM, Nick HP, Breuer W, Cabantchik ZI, Link G. ICL670A: a new synthetic oral chelator: evaluation in hypertransfused rats with selective radioiron probes of hepatocellular and reticuloendothelial iron stores and in iron-loaded rat heart cells in culture. Blood. 2001; 97(4):1115-1122. (Pubitemid 32154301)
70. Wood JC, Kang BP, Thompson A, et al. The effect of deferasirox on cardiac iron in thalassemia major: impact of total body iron stores. Blood. 2010; 116(4):537-543.
71. Galanello R, Agus A, Campus S, Danjou F, Grady R. Combined iron chelation therapy. Ann N Y Acad Sci. 2010;1202:79-86.
72. Davis BA, Porter JB. Long-term outcome of continuous 24-hour deferoxamine infusion via indwelling intravenous catheters in high-risk betathalassemia. Blood. 2000;95(4):1229-1236. (Pubitemid 30099831)
73. Anderson LJ, Westwood MA, Holden S, et al. Myocardial iron clearance during reversal of siderotic cardiomyopathy with intravenous desferrioxamine: a prospective study using T2* cardiovascular magnetic resonance. Br J Haematol. 2004;127(3):348-355. (Pubitemid 39468951)
74. Mamtani M, Kulkarni H. Influence of iron chelators on myocardial iron and cardiac function in transfusion-dependent thalassaemia: a systematic review and meta-analysis. Br J Haematol. 2008;141(6):882-890. (Pubitemid 351724860)
75. Kazazian HH Jr. The thalassemia syndromes: molecular basis and prenatal diagnosis in 1990. Semin Hematol. 1990;27(3):209-228.
76. Petrou M. Preimplantation genetic diagnosis. Hemoglobin. 2009;33(suppl 1):S7-S13.
77. Chiu RW, Lau TK, Leung TN, Chow KC, Chui DH, Lo YM. Prenatal exclusion of beta thalassaemia major by examination of maternal plasma. Lancet. 2002;360(9338):998-1000. (Pubitemid 35284114)
78. Cheung MC, Goldberg JD, Kan YW. Prenatal diagnosis of sickle cell anaemia and thalassaemia by analysis of fetal cells in maternal blood. Nat Genet. 1996;14(3):264-268.
79. Thomas ED, Buckner CD, Sanders JE, et al. Marrow transplantation for thalassaemia. Lancet. 1982;2(8292):227-229. (Pubitemid 12081767)
80. Angelucci E, Baronciani D. Allogeneic stem cell transplantation for thalassemia major. Haematologica. 2008;93(12):1780-1784.
81. Lucarelli G, Gaziev J. Advances in the allogeneic transplantation for thalassemia. Blood Rev. 2008; 22(2):53-63. (Pubitemid 351282443)
82. Sodani P, Gaziev D, Polchi P, et al. New approach for bone marrow transplantation in patients with class 3 thalassemia aged younger than 17 years. Blood. 2004;104(4):1201-1203. (Pubitemid 39038044)
83. Gaziev D, Polchi P, Galimberti M, et al. Graft-versus-host disease after bone marrow transplantation for thalassemia: an analysis of incidence and risk factors. Transplantation. 1997; 63(6):854-860. (Pubitemid 27150593)
84. Gaziev J, Sodani P, Polchi P, et al. Bone marrow transplantation in adults with thalassemia: treatment and long-term follow-up. Ann N Y Acad Sci. 2005;1054:196-205. (Pubitemid 43031025)
85. Andreani M, Nesci S, Lucarelli G, et al. Long-term survival of ex-thalassemic patients with persistent mixed chimerism after bone marrow transplantation. Bone Marrow Transplant. 2000;25(4):401-404. (Pubitemid 30114034)
86. Angelucci E, Muretto P, Nicolucci A, et al. Effects of iron overload and hepatitis C virus positivity in determining progression of liver fibrosis in thalassemia following bone marrow transplantation. Blood. 2002;100(1):17-21. (Pubitemid 35177422)
87. Boulad F. Hematopoietic stem cell transplantation for the treatment of beta thalassemia. In: Kline R, ed. Pediatric Hematopoietic Stem Cell Transplantation. New York, NY: Informa Healthcare; 2006: 383-396.
88. La Nasa G, Caocci G, Argiolu F, et al. Unrelated donor stem cell transplantation in adult patients with thalassemia. Bone Marrow Transplantation. 2006;36:971-975.
89. Hongeng S, Pakakasama S, Chuansumrit A, et al. Outcomes of transplantation with related and unrelated donor stem cells in children with severe thalassemia. Biol Blood Marrow Transplant. 2006;12(6):683-687. (Pubitemid 44226050)
90. Gaziev J, Sodani P, Lucarelli G, et al. Second hematopoietic SCT in patients with thalassemia recurrence following rejection of the first graft. Bone Marrow Transplant. 2008;42(6):397-404.
91. Boncimino A, Bertaina A, Locatelli F. Cord blood transplantation in patients with hemoglobinopathies. Transfus Apher Sci. 2010;42(3):277-281.
92. Reed W, Walters M, Lubin BH. Collection of sibling donor cord blood for children with thalassemia. J Pediatr Hematol Oncol. 2000;22(6):602-604.
93. Perrine SP. Fetal globin stimulant therapies in the beta- hemoglobinopathies: principles and current potential. Pediatr Ann. 2008;37(5):339-346. (Pubitemid 351847506)
94. Dixit A, Chatterjee TC, Mishra P, et al. Hydroxyurea in thalassemia intermedia: a promising therapy. Ann Hematol. 2005;84(7):441-446. (Pubitemid 40867920)
95. Karimi M, Darzi H, Yavarian M. Haematologic and clinical responses of thelassemia intermedia patients to hydroxyurea during 6 years of therapy in Iran. J Pediatr Hematol Oncol. 2005;27(7):380- 385.
96. Ware RE. How I use hydroxyurea to treat young patients with sickle cell anemia. Blood. 2010; 115(26):5300-5311.
97. Sankaran VG, Xu J, Orkin SH. Advances in the understanding of haemoglobin switching. Br J Haematol. 2010;149(2):181-194.
98. Rivella S, May C, Chadburn A, et al. A novel murine model of Cooley anemia and its rescue by lentiviral-mediated human beta-globin gene transfer. Blood. 2003;101(8):2932-2939. (Pubitemid 36857977)
99. May C, Rivella S, Callegari J, et al. Therapeutic haemoglobin synthesis in beta-thalassaemic mice expressing lentivirus-encoded human betaglobin. Nature. 2000;406(6791):82-86. (Pubitemid 30460215)
100. Breda L, Kleinert D, Casu C, et al. A preclinical approach for gene therapy of beta-thalassemia. Ann N Y Acad Sci. 2010;1202:134-140.
101. Breda L, Rivella S. Gene therapy in thalassemia and hemoglobinopathies. Mediterr J Hematol Infect Dis. 2009;1:1.
102. Rivella S, Rachmilewitz E. Future alternative therapies for beta-thalassemia. Expert Rev Hematol. 2009;2(6):685.
103. Cavazzana-Calvo M, Payen E, Negre O, et al. Transfusion independence and HMGA2 activation after gene therapy of human beta-thalassemia. Nature. 2010;467(7313):277-278.
104. Sadelain M, Riviere I, Wang X, et al. Strategy for a multicenter phase I clinical trial to evaluate globin gene transfer in beta-thalassemia. Ann N Y Acad Sci. 2010;1202:52-58.